Compare WASH & FDMT Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | WASH | FDMT |
|---|---|---|
| Founded | 1800 | 2013 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Major Banks | Biotechnology: Pharmaceutical Preparations |
| Sector | Finance | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 765.5M | 695.3M |
| IPO Year | 1994 | 2019 |
| Metric | WASH | FDMT |
|---|---|---|
| Price | $38.68 | $12.31 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 4 | 12 |
| Target Price | ★ $38.67 | $28.09 |
| AVG Volume (30 Days) | 123.7K | ★ 933.5K |
| Earning Date | 10-19-2026 | 11-17-2026 |
| Dividend Yield | ★ 5.79% | N/A |
| EPS Growth | ★ 266.26 | 18.79 |
| EPS | ★ 2.50 | N/A |
| Revenue | ★ $229,048,000.00 | $85,209,000.00 |
| Revenue This Year | $10.76 | N/A |
| Revenue Next Year | $6.48 | $55.65 |
| P/E Ratio | $27.03 | ★ N/A |
| Revenue Growth | 127.57 | ★ 230194.60 |
| 52 Week Low | $26.52 | $6.96 |
| 52 Week High | $40.90 | $16.93 |
| Indicator | WASH | FDMT |
|---|---|---|
| Relative Strength Index (RSI) | 50.41 | 48.92 |
| Support Level | $38.43 | $8.68 |
| Resistance Level | $40.28 | $13.64 |
| Average True Range (ATR) | 1.02 | 1.02 |
| MACD | 0.08 | 0.05 |
| Stochastic Oscillator | 32.95 | 58.89 |
Washington Trust Bancorp Inc through its subsidiaries, offers banking and financial services to individuals and businesses. It offers a full range of financial services, including commercial banking, mortgage banking, personal banking, wealth management, and trust services, through its offices located in Rhode Island, Connecticut, and Massachusetts. It operates in two segments. The Commercial Banking segment includes lending activities, commercial loans, residential real estate loan deposit activities, and others. The Wealth Management Services segment consists of investment management, financial planning, personal trust, and estate services, including services as trustee, personal representative, custodian, and guardian, and settlement of decedents' estates.
4D Molecular Therapeutics Inc is biotechnology company advancing durable and disease-targeted therapeutics with potential to transform treatment paradigms and provide unprecedented benefits to patients. Companies focus is on advancing 4D-150 for wet age-related macular degeneration (wet AMD) and diabetic macular edema (DME) through late-stage studies. It has built a portfolio of gene therapy product candidates focused on three therapeutic areas: Ophthalmology (intravitreal vector) includes 4D-150, 4D-710 and 4D-175; Cardiology (intravenous vector) includes 4D-710, 4D-725, and Pulmonology (aerosol vector).